Protalix BioTherapeutics ... (PLX)
AMEX: PLX
· Real-Time Price · USD
2.99
-0.08 (-2.61%)
At close: May 01, 2025, 3:59 PM
3.00
0.27%
After-hours: May 01, 2025, 06:00 PM EDT
Protalix BioTherapeutics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|
| License and Service Revenue | 120K | 3.65M | 5.03M | 3.78M | 5.13M | 3.43M | 6.91M |
| License and Service Revenue Growth | -96.71% | -27.49% | +33.10% | -26.26% | +49.45% | -50.35% | n/a |
| Product Revenue | 17.84M | n/a | n/a | n/a | n/a | n/a | 3.53M |
| Product Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|
| Brazil Revenue | 10.4M | 9.45M | 6.4M |
| Brazil Revenue Growth | +10.04% | +47.69% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.6M | 3.48M | 3.12M | 4.14M | 3.67M | 4.03M | 3.12M | 3.1M | 2.85M | 2.61M | 3.15M | 3.47M | 2.95M | 3.17M | 3.14M | 2.95M | 2.82M | 2.19M | 3.19M | 3.01M | 2.59M | 2.07M | 2.23M | 3.62M | 2.64M | 2.16M | 2.5M | 3.34M | 2.84M | 2.81M | 2.54M | 3.14M | 2.01M | 2.21M | 2M | 1.02M | 2.25M | 2.09M | 1.91M |
| Selling, General, and Administrative Revenue Growth | -25.52% | +11.85% | -24.81% | +12.89% | -8.96% | +29.41% | +0.55% | +8.78% | +9.08% | -17.22% | -9.00% | +17.33% | -6.84% | +1.05% | +6.34% | +4.79% | +28.35% | -31.16% | +5.74% | +16.51% | +25.10% | -7.26% | -38.43% | +37.30% | +22.24% | -13.61% | -25.28% | +17.88% | +0.78% | +10.92% | -19.23% | +55.96% | -8.70% | +10.58% | +95.59% | -54.75% | +7.74% | +9.36% | n/a |
| Research and Development Revenue | 3M | 2.96M | 2.89M | 3.1M | 3.67M | 4.47M | 5.85M | 5.62M | 7.39M | 7.58M | 8.77M | 7.64M | 7.28M | 7.69M | 7.12M | 10.95M | 7.69M | 9.19M | 10.34M | 9.6M | 10M | 13.32M | 11.7M | 9.57M | 10.07M | 7.24M | 6.44M | 8.99M | 6.39M | 8.83M | 4.63M | 5.71M | 5.06M | 7.82M | 6.03M | 5.39M | 4.05M | 4.96M | 5.63M |
| Research and Development Revenue Growth | +1.25% | +2.56% | -6.93% | -15.45% | -18.01% | -23.47% | +4.09% | -23.95% | -2.55% | -13.55% | +14.74% | +4.93% | -5.29% | +7.96% | -34.98% | +42.47% | -16.31% | -11.16% | +7.76% | -4.05% | -24.94% | +13.89% | +22.17% | -4.93% | +39.08% | +12.39% | -28.33% | +40.71% | -27.61% | +90.67% | -18.90% | +12.90% | -35.34% | +29.78% | +11.82% | +32.94% | -18.24% | -11.91% | n/a |
| Sales and Marketing Revenue | 17.84M | n/a | 3.68M | 10.11M | 10.17M | 15.07M | 5.07M | 25.29M | 8.81M | 3.38M | 9.03M | n/a | 4.51M | 3.24M | 4.51M | n/a | 3.3M | 3.65M | 5.03M | 8.98M | 5.13M | 3.43M | 3.53M | 9.2M | 663K | 2.01M | 4.55M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | n/a | -100.00% | -63.63% | -0.58% | -32.55% | +197.57% | -79.97% | +187.02% | +160.56% | -62.54% | n/a | -100.00% | +38.95% | -28.11% | n/a | -100.00% | -9.65% | -27.49% | -43.96% | +75.15% | +49.45% | -2.83% | -61.63% | +1287.48% | -66.95% | -55.94% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |